PRKAR2B

Across TCGA pan-cancer cohorts, PRKAR2B RNA differs between tumor and matched normal tissue in 17 of 18 cancer types tested, making tumor–normal expression one of PRKAR2B’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PRKAR2B RNA is repressed in tumor relative to normal tissue. In most cancer types PRKAR2B is over-expressed in tumor, although a few such as KIRC and BLCA show the opposite, repressed pattern.

KIRC, BLCA, and KICH are the cancer types where PRKAR2B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRKAR2B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−2.005	<.001	12	view →
BLCA	Male	IV	−2.894	<.001	10	view →
KICH	All	III,IV	−2.527	<.001	10	view →
COAD	Male	II,III,IV	−1.528	<.001	10	view →
THCA	Male	All	−1.100	<.001	8	view →
LUSC	Female	II,III,IV	−1.671	<.001	7	view →
LIHC	Male	III,IV	−1.240	<.001	7	view →
UCEC	All	All	−2.819	<.001	6	view →
BRCA	Female	All	−1.850	<.001	6	view →
LUAD	All	III,IV	−0.966	<.001	6	view →
STAD	Male	All	−1.332	<.001	4	view →
HNSC	All	All	−0.637	.005	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 17 lineages.

PRKAR2B–KIRC

Open the KIRC breakdown →